Format

Send to

Choose Destination
See comment in PubMed Commons below
Neurology. 2002 Jun 11;58(11):1680-2.

A crossover, add-on trial of talampanel in patients with refractory partial seizures.

Author information

1
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. aschappell@lilly.com

Abstract

The authors report a double-blind, placebo-controlled, crossover study of talampanel in 49 patients with refractory partial seizures. Three doses of talampanel were investigated based on differences in patients' concomitant antiepileptic drug usage. Talampanel showed efficacy in reducing seizure frequency (p = 0.001) with a median seizure reduction of 21%. Eighty percent of patients had fewer seizures on talampanel than on placebo. Dizziness (52%) and ataxia (26%) were the only significant adverse events.

PMID:
12058100
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center